28
Oct 2026
Cancer-related discrimination arises from long-lasting cultural and institutional misconceptions, with significant impacts on every part of a person's quality of life and health – and Flinders University researchers say it requires coordinated policy, legal, institutional and public education responses for change to occur.
28
Oct 2026
The diagnosed prevalent cases of ulcerative colitis (UC) in the seven major markets (7 MM) are projected to reach over 2.36 million by 2035.
28
Oct 2026
The diagnosed prevalent cases of ulcerative colitis (UC) in the seven major markets (7MM) are projected to reach over 2.36 million by 2035.
28
Oct 2026
DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating complications.
28
Oct 2026
Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.
28
Oct 2026
Alcami, a leading contract development and manufacturing organization (CDMO), today announced its strengthening of laboratory leadership with the promotion of Robert Tragas to Vice President, Laboratory Services.
28
Oct 2026
On the heels of our exciting major investment and Nantworks partnership announcement last week, Prolific Machines is pleased to announce a great new partnership with Zylidac Bio, a fully integrated biologics CDMO located next door to us in San Francisco Bay Area, to scale up the production of Prolific's Optogentics-enabled cell lines for clinical and GMP manufacturing!
28
Oct 2026
NIOX Group plc, a global leader in fractional exhaled nitric oxide (FeNO) testing, has announced the launch of NIOX PRO®, its next-generation FeNO testing device designed to support healthcare professionals in the diagnosis and management of asthma, COPD and other inflammatory airway diseases.
28
Oct 2026
Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced a partnership with Frontier Space, a UK based space biotechnology company building platform technology for in-orbit R&D and biomanufacturing. Under the two-year memorandum of understanding (MoU), the companies will validate Atelerix’s alginate hydrogel encapsulation technology for preserving biological samples during microgravity research missions, improving sample quality and reducing payload mass and associated costs.
27
Oct 2026
It is a dietary staple found in sushi, rice wraps, and ramen toppings. Commonly known as nori in Japan and gim in Korea, red seaweed is especially popular across Asia.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
